Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

Abstract

Apremilast was effective in the treatment of moderate-to-severe plaque psoriasis over 52 weeks.